Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Impact · against what's priced in

Supernus gains significant revenue protection through 2033 via orphan-drug exclusivity for ONAPGO and reduces operational risk by diversifying its supply chain by 2027. Both developments provide a structural floor for high-margin revenue and lower the probability of single-source manufacturing failures.

SUPN+0.70: No priced-in read yet
In context: The FDA grant of seven years of orphan-drug exclusivity prevents generic competition through 2033, while the sNDA for a second supplier by mid-2027 mitigates single-source risk.
Read from the article alone

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

SUPN
biopharma
cns diseases
fda
market exclusivity
orphan drug
parkinsons

Search tags

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

What matters in this story

What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R.

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

What matters in this story

What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R.

How each ticker is affected

Track these names every morning.

Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

BioVie reports positive Phase 2 Parkinson's data for bezisterim

BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

What matters in this story

Next reads from the same story arc

What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R.

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

What matters in this story

Next reads from the same story arc

What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R.

How each ticker is affected

Track these names every morning.

Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

BioVie reports positive Phase 2 Parkinson's data for bezisterim

BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites